

Khalid Shah

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5016547/publications.pdf>

Version: 2024-02-01

98
papers

6,093
citations

94381

37
h-index

74108

75
g-index

121
all docs

121
docs citations

121
times ranked

7619
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 4822-4827.	3.3	425
2	MicroRNA-21 Knockdown Disrupts Glioma Growth <i>In vivo</i> and Displays Synergistic Cytotoxicity with Neural Precursor Cell-Delivered S-TRAIL in Human Gliomas. Cancer Research, 2007, 67, 8994-9000.	0.4	416
3	Mesenchymal Stem Cell Immunomodulation: Mechanisms and Therapeutic Potential. Trends in Pharmacological Sciences, 2020, 41, 653-664.	4.0	379
4	Shattering barriers toward clinically meaningful MSC therapies. Science Advances, 2020, 6, eaba6884.	4.7	351
5	Human Glioblastoma-Derived Cancer Stem Cells: Establishment of Invasive Glioma Models and Treatment with Oncolytic Herpes Simplex Virus Vectors. Cancer Research, 2009, 69, 3472-3481.	0.4	303
6	Mesenchymal stem cells engineered for cancer therapy. Advanced Drug Delivery Reviews, 2012, 64, 739-748.	6.6	285
7	TRAIL on trial: preclinical advances in cancer therapy. Trends in Molecular Medicine, 2013, 19, 685-694.	3.5	243
8	Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression. Cancer Discovery, 2014, 4, 1299-1309.	7.7	207
9	Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas. Nature Neuroscience, 2012, 15, 197-204.	7.1	194
10	Stem cell-based therapies for cancer treatment: separating hope from hype. Nature Reviews Cancer, 2014, 14, 683-691.	12.8	190
11	Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression. Annals of Neurology, 2005, 57, 34-41.	2.8	188
12	Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics. Frontiers in Oncology, 2020, 10, 1182.	1.3	167
13	Molecular optical imaging: Applications leading to the development of present day therapeutics. NeuroRx, 2005, 2, 215-225.	6.0	165
14	Real-time imaging of TRAIL-induced apoptosis of glioma tumors <i>in vivo</i> . Oncogene, 2003, 22, 6865-6872.	2.6	128
15	<i>In vivo</i> imaging of S-TRAIL-mediated tumor regression and apoptosis. Molecular Therapy, 2005, 11, 926-931.	3.7	105
16	Stem Cells Loaded With Multimechanistic Oncolytic Herpes Simplex Virus Variants for Brain Tumor Therapy. Journal of the National Cancer Institute, 2014, 106, dju090.	3.0	102
17	Bimodal Viral Vectors and <i>In Vivo</i> Imaging Reveal the Fate of Human Neural Stem Cells in Experimental Glioma Model. Journal of Neuroscience, 2008, 28, 4406-4413.	1.7	98
18	Encapsulated Stem Cells Loaded With Hyaluronidase-expressing Oncolytic Virus for Brain Tumor Therapy. Molecular Therapy, 2015, 23, 108-118.	3.7	97

#	ARTICLE	IF	CITATIONS
19	A Dual PI3K/mTOR Inhibitor, PI-103, Cooperates with Stem Cell-Delivered TRAIL in Experimental Glioma Models. <i>Cancer Research</i> , 2011, 71, 154-163.	0.4	94
20	Inducible Release of TRAIL Fusion Proteins from a Proapoptotic Form for Tumor Therapy. <i>Cancer Research</i> , 2004, 64, 3236-3242.	0.4	91
21	Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E6157-E6165.	3.3	90
22	Therapeutic Efficacy and Fate of Bimodal Engineered Stem Cells in Malignant Brain Tumors. <i>Stem Cells</i> , 2013, 31, 1706-1714.	1.4	89
23	Immune phenotyping of diverse syngeneic murine brain tumors identifies immunologically distinct types. <i>Nature Communications</i> , 2020, 11, 3912.	5.8	81
24	Microbiota and the gut-brain-axis: Implications for new therapeutic design in the CNS. <i>EBioMedicine</i> , 2022, 77, 103908.	2.7	80
25	Tumor Therapy Mediated by Lentiviral Expression of shBcl-2 and S-TRAIL. <i>Neoplasia</i> , 2007, 9, 435-442.	2.3	71
26	Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 16642-16647.	3.3	70
27	TRAIL of Hope Meeting Resistance in Cancer. <i>Trends in Cancer</i> , 2020, 6, 989-1001.	3.8	70
28	A Novel Molecule Integrating Therapeutic and Diagnostic Activities Reveals Multiple Aspects of Stem Cell-based Therapy. <i>Stem Cells</i> , 2010, 28, 832-841.	1.4	54
29	Direct Tumor Killing and Immunotherapy through Anti-SerpineB9 Therapy. <i>Cell</i> , 2020, 183, 1219-1233.e18.	13.5	54
30	Stem cell-based therapies for tumors in the brain: are we there yet?. <i>Neuro-Oncology</i> , 2016, 18, 1066-1078.	0.6	52
31	In Vivo Imaging of HIV Protease Activity in Amplicon Vector-transduced Gliomas. <i>Cancer Research</i> , 2004, 64, 273-278.	0.4	51
32	TOX Regulates Growth, DNA Repair, and Genomic Instability in T-cell Acute Lymphoblastic Leukemia. <i>Cancer Discovery</i> , 2017, 7, 1336-1353.	7.7	48
33	Multimechanistic Tumor Targeted Oncolytic Virus Overcomes Resistance in Brain Tumors. <i>Molecular Therapy</i> , 2013, 21, 68-77.	3.7	46
34	Antiangiogenic Variant of TSP-1 Targets Tumor Cells in Glioblastomas. <i>Molecular Therapy</i> , 2015, 23, 235-243.	3.7	44
35	Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus. <i>Molecular Cell</i> , 2020, 78, 1207-1223.e8.	4.5	43
36	Encapsulated stem cells for cancer therapy. <i>Biomatter</i> , 2013, 3, .	2.6	42

#	ARTICLE	IF	CITATIONS
37	Mesenchymal stem cell immunomodulation: In pursuit of controlling COVID-19 related cytokine storm. <i>Stem Cells</i> , 2021, 39, 707-722.	1.4	42
38	Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 889-902.	3.2	41
39	Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumors. <i>Scientific Reports</i> , 2017, 7, 2602.	1.6	40
40	AEG-1 Regulates Retinoid X Receptor and Inhibits Retinoid Signaling. <i>Cancer Research</i> , 2014, 74, 4364-4377.	0.4	39
41	CRISPR-enhanced engineering of therapy-sensitive cancer cells for self-targeting of primary and metastatic tumors. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	39
42	Targeting breast to brain metastatic tumours with death receptor ligand expressing therapeutic stem cells. <i>Brain</i> , 2015, 138, 1710-1721.	3.7	38
43	Multifunctional receptor-targeting antibodies for cancer therapy. <i>Lancet Oncology</i> , The, 2015, 16, e543-e554.	5.1	36
44	Tumor Resection Recruits Effector T Cells and Boosts Therapeutic Efficacy of Encapsulated Stem Cells Expressing IFN γ in Glioblastomas. <i>Clinical Cancer Research</i> , 2017, 23, 7047-7058.	3.2	36
45	Multiple lesions in receptor tyrosine kinase pathway determine glioblastoma response to pan-ERBB inhibitor PF-00299804 and PI3K/mTOR dual inhibitor PF-05212384. <i>Cancer Biology and Therapy</i> , 2014, 15, 815-822.	1.5	35
46	Combination of Systemic Chemotherapy with Local Stem Cell Delivered S-TRAIL in Resected Brain Tumors. <i>Stem Cells</i> , 2015, 33, 101-110.	1.4	34
47	Pre-clinical tumor models of primary brain tumors: Challenges and opportunities. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188458.	3.3	34
48	microRNA-7 upregulates death receptor 5 and primes resistant brain tumors to caspase-mediated apoptosis. <i>Neuro-Oncology</i> , 2018, 20, 215-224.	0.6	32
49	Simultaneous downregulation of miR-21 and upregulation of miR-7 has anti-tumor efficacy. <i>Scientific Reports</i> , 2020, 10, 1779.	1.6	29
50	The Potential of the Gut Microbiome to Reshape the Cancer Therapy Paradigm. <i>JAMA Oncology</i> , 2022, 8, 1059.	3.4	29
51	Arginine deprivation alters microglial polarity and synergizes with radiation to eradicate non-arginine-auxotrophic glioblastoma tumors. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	28
52	Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus. <i>International Journal of Cancer</i> , 2017, 141, 1671-1681.	2.3	26
53	Simultaneous targeting of primary tumor, draining lymph node, and distant metastases through high endothelial venule-targeted delivery. <i>Nano Today</i> , 2021, 36, 101045.	6.2	24
54	Oncolytic Herpes Simplex Virus-Based Therapies for Cancer. <i>Cells</i> , 2021, 10, 1541.	1.8	24

#	ARTICLE	IF	CITATIONS
55	Neural Precursor Cells and Their Role in Neuro-Oncology. <i>Developmental Neuroscience</i> , 2004, 26, 118-130.	1.0	22
56	HSV Amplicon Vectors for Cancer Therapy. <i>Current Gene Therapy</i> , 2006, 6, 361-370.	0.9	19
57	Therapy-Induced Tumor Cell Death: Friend or Foe of Immunotherapy?. <i>Frontiers in Oncology</i> , 2021, 11, 678562.	1.3	15
58	Targeting c-Met Receptor Overcomes TRAIL-Resistance in Brain Tumors. <i>PLoS ONE</i> , 2014, 9, e95490.	1.1	14
59	Poly(beta-amino ester) nanoparticles enable tumor-specific TRAIL secretion and a bystander effect to treat liver cancer. <i>Molecular Therapy - Oncolytics</i> , 2021, 21, 377-388.	2.0	12
60	Molecular Imaging with Bioluminescence and PET Reveals Viral Oncolysis Kinetics and Tumor Viability. <i>Cancer Research</i> , 2014, 74, 4111-4121.	0.4	11
61	Stem Cell-Based Therapies for Cancer. <i>Advances in Cancer Research</i> , 2015, 127, 159-189.	1.9	11
62	Somatostatin receptor type 2 as a radiotheranostic PET reporter gene for oncologic interventions. <i>Theranostics</i> , 2018, 8, 3380-3391.	4.6	11
63	Tricistronic expression of MOAP-1, Bax and RASSF1A in cancer cells enhances chemo-sensitization that requires BH3L domain of MOAP-1. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1751-1764.	1.2	11
64	Immunotherapy in hematological malignancies: recent advances and open questions. <i>Immunotherapy</i> , 2021, 13, 1215-1229.	1.0	11
65	Anti-EGFR VHH-armed death receptor ligand-engineered allogeneic stem cells have therapeutic efficacy in diverse brain metastatic breast cancers. <i>Science Advances</i> , 2021, 7, .	4.7	10
66	PET imaging of glioblastoma multiforme EGFR expression for therapeutic decision guidance. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 5, 379-89.	1.0	10
67	NK cells in the brain: implications for brain tumor development and therapy. <i>Trends in Molecular Medicine</i> , 2022, 28, 194-209.	3.5	10
68	Target receptor identification and subsequent treatment of resected brain tumors with encapsulated and engineered allogeneic stem cells. <i>Nature Communications</i> , 2022, 13, 2810.	5.8	10
69	Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy. <i>Scientific Reports</i> , 2019, 9, 139.	1.6	9
70	Imaging Neural Stem Cell Fate in Mouse Model of Glioma. , 2009, Chapter 5, Unit 5A.1.		9
71	Modulating microRNAs in cancer: Next-generation therapies. <i>Cancer Biology and Medicine</i> , 2021, , 1-1.	1.4	9
72	Stem Cells Engineered During Different Stages of Reprogramming Reveal Varying Therapeutic Efficacies. <i>Stem Cells</i> , 2018, 36, 932-942.	1.4	7

#	ARTICLE	IF	CITATIONS
73	Engineered stem cells targeting multiple cell surface receptors in tumors. <i>Stem Cells</i> , 2020, 38, 34-44.	1.4	7
74	Next-generation immunotherapies for brain metastatic cancers. <i>Trends in Cancer</i> , 2021, 7, 809-822.	3.8	6
75	A model of breast cancer meningeal metastases: characterization with in vivo molecular imaging. <i>Cancer Gene Therapy</i> , 2019, 26, 145-156.	2.2	5
76	Immune Profiling of Syngeneic Murine and Patient GBMs for Effective Translation of Immunotherapies. <i>Cells</i> , 2021, 10, 491.	1.8	5
77	Generation of TRAIL-resistant cell line models reveals distinct adaptive mechanisms for acquired resistance and re-sensitization. <i>Oncogene</i> , 2021, 40, 3201-3216.	2.6	5
78	IL13R α 2 and EGFR targeted pseudomonas exotoxin potentiates the TRAIL mediated death of GBM cells. <i>International Journal of Molecular Medicine</i> , 2021, 48, .	1.8	5
79	Tartary buckwheat extract alleviates alcohol-induced acute and chronic liver injuries through the inhibition of oxidative stress and mitochondrial cell death pathway. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 70-89.	0.0	5
80	Neurons from human mesenchymal stem cells display both spontaneous and stimuli responsive activity. <i>PLoS ONE</i> , 2020, 15, e0228510.	1.1	4
81	BAP1 and YY1 regulate expression of death receptors in malignant pleural mesothelioma. <i>Journal of Biological Chemistry</i> , 2021, 297, 101223.	1.6	3
82	Mesenchymal Stem Cell-Based COVID-19 Therapy: Bioengineering Perspectives. <i>Cells</i> , 2022, 11, 465.	1.8	3
83	Engineered bifunctional proteins and stem cells: next generation of targeted cancer therapeutics. <i>Discovery Medicine</i> , 2016, 22, 157-166.	0.5	3
84	Response. <i>Journal of the National Cancer Institute</i> , 2014, 107, dju370-dju370.	3.0	1
85	Imaging Fate of Stem Cells at a Cellular Resolution in the Brains of Mice. <i>Methods in Molecular Biology</i> , 2011, 680, 91-101.	0.4	1
86	In Vivo Imaging of the Dynamics of Different Variants of EGFR in Glioblastomas. <i>Methods in Molecular Biology</i> , 2011, 680, 153-164.	0.4	1
87	SCDT-26. STEM CELL LOADED ONCOLYTIC VIRUSES TRACK AND KILL METASTATIC BRAIN TUMORS. <i>Neuro-Oncology</i> , 2017, 19, vi270-vi270.	0.6	0
88	STEM-02. DEVELOPING BRAIN METASTATIC TUMOR MODELS FOR TARGETED STEM CELL THERAPY. <i>Neuro-Oncology</i> , 2018, 20, vi243-vi244.	0.6	0
89	EXTH-49. THERAPEUTIC EFFICACY OF ENGINEERED, HYDROGEL ENCAPSULATED BIMODAL MSC IN GLIOBLASTOMA STRATIFIED ON CELL SURFACE RECEPTOR EXPRESSION. <i>Neuro-Oncology</i> , 2019, 21, vi93-vi93.	0.6	0
90	TMIC-25. MODIFICATION OF EXTRACELLULAR MATRIX ENHANCES ONCOLYTIC ADENOVIRUS IMMUNOTHERAPY IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2019, 21, vi252-vi253.	0.6	0

#	ARTICLE	IF	CITATIONS
91	OMRT-14. Small molecule circadian clock compounds exhibit potential as a novel therapy paradigm for glioblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, ii9-ii9.	0.4	0
92	OTHR-02. Engineered "off the shelf" allogeneic cellular therapies for metastatic brain tumors. <i>Neuro-Oncology Advances</i> , 2021, 3, iii14-iii14.	0.4	0
93	Molecular optical imaging: Applications leading to the development of present day therapeutics. <i>Neurotherapeutics</i> , 2005, 2, 215-225.	2.1	0
94	TMOD-01. DEVELOPING CLINICALLY RELEVANT BRAIN METASTATIC TUMOR MODELS FOR TARGETED STEM CELL THERAPEUTICS. <i>Neuro-Oncology</i> , 2020, 22, ii227-ii227.	0.6	0
95	Neurons from human mesenchymal stem cells display both spontaneous and stimuli responsive activity. , 2020, 15, e0228510.		0
96	Neurons from human mesenchymal stem cells display both spontaneous and stimuli responsive activity. , 2020, 15, e0228510.		0
97	Neurons from human mesenchymal stem cells display both spontaneous and stimuli responsive activity. , 2020, 15, e0228510.		0
98	Neurons from human mesenchymal stem cells display both spontaneous and stimuli responsive activity. , 2020, 15, e0228510.		0